Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Adaptive Biotechnologies Corporation
  6. Summary
    ADPT   US00650F1093

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(ADPT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
25.19(c) 26.23(c) 25.36(c) 25.17(c) 27.63(c) Last
855 331 736 435 1 543 467 873 122 843 422 Volume
-3.45% +4.13% -3.32% -0.75% +9.77% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 153 M - -
Net income 2021 -211 M - -
Net cash position 2021 273 M - -
P/E ratio 2021 -18,5x
Yield 2021 -
Sales 2022 197 M - -
Net income 2022 -241 M - -
Net cash position 2022 106 M - -
P/E ratio 2022 -16,5x
Yield 2022 -
Capitalization 3 899 M 3 899 M -
EV / Sales 2021 23,7x
EV / Sales 2022 19,3x
Nbr of Employees 622
Free-Float 98,5%
More Financials
Company
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and... 
Read more
Sector
Biotechnology & Medical Research
Calendar
12/11 | 05:30pmPresentation
More about the company
Ratings of Adaptive Biotechnologies Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about ADAPTIVE BIOTECHNOLOGIES CORPORATION
12/02Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts on Utility..
AQ
12/02Adaptive Biotechnologies Corporation Present More than 30 Abstracts on Utility of clono..
CI
11/11Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Di..
GL
11/11Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Di..
GL
11/11Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Di..
CI
11/03Adaptive Biotechnologies Q3 2021 Earnings Presentation
PU
11/03ADAPTIVE BIOTECHNOLOGIES : Q3 Earnings Snapshot
AQ
11/03Adaptive Biotechnologies Reports Narrower-Than-Expected Loss, Revenue Tops Estimates
MT
11/03Adaptive Biotechnologies Reports Third Quarter 2021 Financial Results - Form 8-K
PU
11/03ADAPTIVE BIOTECHNOLOGIES CORP Management's Discussion and Analysis of Financial Condit..
AQ
11/03Adaptive Biotechnologies Corporation Reports Earnings Results for the Third Quarter and..
CI
11/03ADAPTIVE BIOTECHNOLOGIES CORP : Results of Operations and Financial Condition, Change in D..
AQ
11/03Adaptive Biotechnologies Corporation Designates Kyle Piskel as the Company's Principal ..
CI
11/03Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Posts Q3 Revenue $39.5M, vs. Street Est ..
MT
11/03Adaptive Biotechnologies Reports Third Quarter 2021 Financial Results
GL
More news
News in other languages on ADAPTIVE BIOTECHNOLOGIES CORPORATION
11/03Adaptive Biotechnologies enregistre une perte plus étroite que prévu, mais son chiffre ..
11/03Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES affiche un chiffre d'affaires de 39,5 mi..
11/03Adaptive Biotechnologies réitère ses prévisions de revenus pour l'ensemble de l'année 2..
08/05Adaptive Biotechnologies nomme un responsable commercial en chef
08/04Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES annonce un chiffre d'affaires de 38,5 mi..
More news
Analyst Recommendations on ADAPTIVE BIOTECHNOLOGIES CORPORATION
More recommendations
Chart ADAPTIVE BIOTECHNOLOGIES CORPORATION
Duration : Period :
Adaptive Biotechnologies Corporation Technical Analysis Chart | ADPT | US00650F1093 | MarketScreener
Technical analysis trends ADAPTIVE BIOTECHNOLOGIES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 27,63 $
Average target price 56,00 $
Spread / Average Target 103%
EPS Revisions
Managers and Directors
Chad Robins Chairman & Chief Executive Officer
Julie Rubinstein President
Chad M. Cohen Chief Financial Officer
Harlan Robins Chief Scientific Officer
Lance Baldo Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ADAPTIVE BIOTECHNOLOGIES CORPORATION-53.27%3 899
EXACT SCIENCES CORPORATION-42.19%14 364
GUARDANT HEALTH, INC.-31.17%9 697
BGI GENOMICS CO., LTD.-30.00%5 793
INVITAE CORPORATION-59.22%3 860
IOVANCE BIOTHERAPEUTICS, INC.-59.53%2 947